Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of telitacicept in generalized myasthenia gravis
CTR20253415Phase 3Active
- Sponsor
- RemeGen
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in myasthenia gravis (MG), sponsored by RemeGen. Started Apr 2026; status: active.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20253415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253415.